{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T21:39:57Z","timestamp":1767908397032,"version":"3.49.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T00:00:00Z","timestamp":1509062400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00115-017-0440-x","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T06:05:30Z","timestamp":1509084330000},"page":"184-192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Neues zur symptomatischen MS-Therapie: Teil\u00a03 \u2013 Blasenfunktionsst\u00f6rungen","What is new in symptomatic MS treatment: Part\u00a03\u2014bladder dysfunction"],"prefix":"10.1007","volume":"89","author":[{"given":"T.","family":"Henze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Feneberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Flachenecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Starck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. G.","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,27]]},"reference":[{"key":"440_CR1","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1177\/1352458513489758","volume":"19","author":"G Amarenco","year":"2013","unstructured":"Amarenco G, Chartier-Kastler E, Denys P et al (2013) First-line urological evaluation in multiple sclerosis: validation of a\u00a0specific decision-making algorithm. Mult Scler 19:1931\u20131937","journal-title":"Mult Scler"},{"key":"440_CR2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.rehab.2014.05.006","volume":"57","author":"G Amarenco","year":"2014","unstructured":"Amarenco G, de Seze M, Ruffion A et\u00a0al (2014) Clinical and urodynamic evaluations of urinary disorders in multiple sclerosis. Ann Phys Rehabil Med 57:277\u2013287","journal-title":"Ann Phys Rehabil Med"},{"key":"440_CR3","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1007\/s00120-007-1425-3","volume":"46","author":"J Pannek","year":"2007","unstructured":"Pannek J, Mark R, St\u00f6hrer M et al (2007) Quality of life in German-speaking patients with spinal cord injuries and bladder dysfunctions. Validation of the German version of the Qualiveen questionnaire. Urologe\u00a0A 46:1416\u20131421","journal-title":"Urologe A"},{"key":"440_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001308.pub2","author":"SA Wallace","year":"2004","unstructured":"Wallace SA, Roe B, Williams K et\u00a0al (2004) Bladder training for urinary incontinence in adults. Cochrane Database Syst Rev. \n                        https:\/\/doi.org\/10.1002\/14651858.CD001308.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 1","key":"440_CR5","first-page":"2","volume":"75","author":"T Henze","year":"2004","unstructured":"Henze T, Rieckmann P, Toyka KV (2004) Symptomatische Therapie der Multiplen Sklerose. Nervenarzt 75(Suppl 1):2\u201339","journal-title":"Nervenarzt"},{"key":"440_CR6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.urology.2003.08.047","volume":"63","author":"AC Wang","year":"2004","unstructured":"Wang AC, Wang YY, Chen MC (2004) Single-blind, randomized trial of pelvic floor muscle training, biofeedback-assisted pelvic floor muscle training, and electrical stimulation in the management of overactive bladder. Urology 63:61\u201366","journal-title":"Urology"},{"key":"440_CR7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/nau.20486","volume":"27","author":"D McClurg","year":"2008","unstructured":"McClurg D, Ashe RG, Lowe-Strong AS (2008) Neuromuscular electrical stimulation and the treatment of lower urinary tract dysfunction in multiple sclerosis \u2014 a double blind, placebo controlled, randomised clinical trial. Neurourol Urodyn 27:231\u2013237","journal-title":"Neurourol Urodyn"},{"key":"440_CR8","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/nau.20958","volume":"30","author":"M Seze de","year":"2011","unstructured":"de Seze M, Raibaut P, Gallien P et\u00a0al (2011) Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a\u00a0multicenter prospective study. Neurourol Urodyn 30:306\u2013311","journal-title":"Neurourol Urodyn"},{"key":"440_CR9","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1177\/1352458511414040","volume":"17","author":"C Gobbi","year":"2011","unstructured":"Gobbi C, Digesu GA, Khullar V et\u00a0al (2011) Percutaneous posterior tibial nerve stimulation as an effective treatment of refractory lower urinary tract symptoms in patients with multiple sclerosis: preliminary data from a\u00a0multicentre, prospective, open label trial. Mult Scler 17:1514\u20131519","journal-title":"Mult Scler"},{"key":"440_CR10","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1177\/1352458514531520","volume":"20","author":"AC Lucio","year":"2014","unstructured":"Lucio AC, D\u2019Ancona CA, Lopes MH et\u00a0al (2014) The effect of pelvic floor muscle training alone or in combination with electrostimulation in the treatment of sexual dysfunction in women with multiple sclerosis. Mult Scler 20:1761\u20131768","journal-title":"Mult Scler"},{"key":"440_CR11","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/jnnp.2010.206623","volume":"81","author":"F Khan","year":"2010","unstructured":"Khan F, Pallant JF, Pallant JI et\u00a0al (2010) A randomised controlled trial: outcomes of bladder rehabilitation in persons with multiple sclerosis. J\u00a0Neurol Neurosurg Psychiatry 81:1033\u20131038","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"440_CR12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/WON.0000000000000223","volume":"43","author":"A Lucio","year":"2016","unstructured":"Lucio A, D\u2019Ancona CA, Perissinotto MC et\u00a0al (2016) Pelvic floor muscle training with and without electrical stimulation in the treatment of lower urinary tract symptoms in women with multiple sclerosis. J\u00a0Wound Ostomy Continence Nurs 43:414\u2013419","journal-title":"J Wound Ostomy Continence Nurs"},{"key":"440_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PHM.0000000000000302","volume":"95","author":"AP Ferreira","year":"2016","unstructured":"Ferreira AP, Pegorare AB, Salgado PR et\u00a0al (2016) Impact of a\u00a0pelvic floor training program among women with multiple sclerosis: a controlled clinical trial. Am J Phys Med Rehabil 95:1\u20138","journal-title":"Am J Phys Med Rehabil"},{"key":"440_CR14","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2012.02.036","volume":"62","author":"P Madhuvrata","year":"2012","unstructured":"Madhuvrata P, Singh M, Hasafa Z et al (2012) Anticholinergic drugs for adult neurogenic detrusor overactivity: a\u00a0systematic review and meta-analysis. Eur Urol 62:816\u2013830","journal-title":"Eur Urol"},{"key":"440_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004193","author":"RS Nicholas","year":"2009","unstructured":"Nicholas RS, Friede T, Hollis S et\u00a0al (2009) Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev. \n                        https:\/\/doi.org\/10.1002\/14651858.CD004193","journal-title":"Cochrane Database Syst Rev"},{"key":"440_CR16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrurol.2016.53","volume":"13","author":"V Phe","year":"2016","unstructured":"Phe V, Chartier-Kastler E, Panicker JN (2016) Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol 13:275\u2013288","journal-title":"Nat Rev Urol"},{"key":"440_CR17","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/10790268.2004.11753751","volume":"27","author":"KD Ethans","year":"2004","unstructured":"Ethans KD, Nance PW, Bard RJ et\u00a0al (2004) Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J\u00a0Spinal Cord Med 27:214\u2013218","journal-title":"J Spinal Cord Med"},{"key":"440_CR18","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1474-4422(15)00070-8","volume":"14","author":"JN Panicker","year":"2015","unstructured":"Panicker JN, Fowler CJ, Kessler TM (2015) Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol 14:720\u2013732","journal-title":"Lancet Neurol"},{"key":"440_CR19","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.eururo.2008.01.007","volume":"53","author":"B Amend","year":"2008","unstructured":"Amend B, Hennenlotter J, Sch\u00e4fer T et al (2008) Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 53:1021\u20131028","journal-title":"Eur Urol"},{"key":"440_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.2005.00431.x","volume":"112","author":"R Bosma","year":"2005","unstructured":"Bosma R, Wynia K, Havlikova E et al (2005) Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a\u00a0meta-analysis. Acta Neurol Scand 112:1\u20135","journal-title":"Acta Neurol Scand"},{"key":"440_CR21","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s00192-006-0086-x","volume":"17","author":"RM Freeman","year":"2006","unstructured":"Freeman RM, Adekanmi O, Waterfield MR et al (2006) The effect of cannabis on urge incontinence in patients with multiple sclerosis: a\u00a0multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol\u00a0J 17:636\u2013641","journal-title":"Int Urogynecol J"},{"key":"440_CR22","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1191\/1352458504ms1063oa","volume":"10","author":"CM Brady","year":"2004","unstructured":"Brady CM, DasGupta R, Dalton C et al (2004) An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 10:425\u2013433","journal-title":"Mult Scler"},{"key":"440_CR23","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1177\/1352458510378020","volume":"16","author":"RB Kavia","year":"2010","unstructured":"Kavia RB, De Ridder D, Constantinescu CS et\u00a0al (2010) Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler 16:1349\u20131359","journal-title":"Mult Scler"},{"key":"440_CR24","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/WNF.0b013e3182996400","volume":"36","author":"C Solaro","year":"2013","unstructured":"Solaro C, Bergamaschi R, Rezzani C et al (2013) Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study. Clin Neuropharmacol 36:114\u2013116","journal-title":"Clin Neuropharmacol"},{"key":"440_CR25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/WNF.0b013e3182613dce","volume":"35","author":"S Rezze Di","year":"2012","unstructured":"Di Rezze S, Frasca V, Inghilleri M et\u00a0al (2012) Duloxetine for the treatment of overactive bladder syndrome in multiple sclerosis: a\u00a0pilot study. Clin Neuropharmacol 35:231\u2013234","journal-title":"Clin Neuropharmacol"},{"key":"440_CR26","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.juro.2009.05.038","volume":"182","author":"AP Cameron","year":"2009","unstructured":"Cameron AP, Clemens JQ, Latini JM et\u00a0al (2009) Combination drug therapy improves compliance of the neurogenic bladder. J\u00a0Urol 182:1062\u20131067","journal-title":"J Urol"},{"key":"440_CR27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s001929970003","volume":"10","author":"HP Drutz","year":"1999","unstructured":"Drutz HP, Appell RA, Gleason D et\u00a0al (1999) Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol\u00a0J 10:283\u2013289","journal-title":"Int Urogynecol J"},{"key":"440_CR28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0301-2115(00)00561-3","volume":"98","author":"B Jacquetin","year":"2001","unstructured":"Jacquetin B, Wyndaele J (2001) Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. Eur J Obstet Gynecol Reprod Biol 98:97\u2013102","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"440_CR29","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1046\/j.1464-410x.2000.00575.x","volume":"85","author":"L Cardozo","year":"2000","unstructured":"Cardozo L, Chapple CR, Toozs-Hobson P et al (2000) Efficacy of trospium chloride in patients with detrusor instability: a\u00a0placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int 85:659\u2013664","journal-title":"BJU Int"},{"key":"440_CR30","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.sc.3100750","volume":"37","author":"M St\u00f6hrer","year":"1999","unstructured":"St\u00f6hrer M, Madersbacher H, Richter R et al (1999) Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia \u2014 a double-blind, placebo-controlled clinical trial. Spinal Cord 37:196\u2013200","journal-title":"Spinal Cord"},{"key":"440_CR31","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s12325-013-0054-z","volume":"30","author":"D Ginsberg","year":"2013","unstructured":"Ginsberg D, Cruz F, Herschorn S et\u00a0al (2013) OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology. Adv Ther 30:819\u2013833","journal-title":"Adv Ther"},{"key":"440_CR32","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/sc.2008.25","volume":"46","author":"MJ Hess","year":"2008","unstructured":"Hess MJ, Hess PE, Sullivan MR et\u00a0al (2008) Evaluation of cranberry tablets for the prevention of urinary tract infections in spinal cord injured patients with neurogenic bladder. Spinal Cord 46:622\u2013626","journal-title":"Spinal Cord"},{"key":"440_CR33","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2165\/00003495-200969070-00002","volume":"69","author":"DR Guay","year":"2009","unstructured":"Guay DR (2009) Cranberry and urinary tract infections. Drugs 69:775\u2013807","journal-title":"Drugs"},{"key":"440_CR34","first-page":"988","volume":"172","author":"CH Wang","year":"2012","unstructured":"Wang CH, Fang CC, Chen NC et al (2012) Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a\u00a0systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 172:988\u2013996","journal-title":"Arch Intern Med"},{"key":"440_CR35","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1177\/1352458513517592","volume":"20","author":"P Gallien","year":"2014","unstructured":"Gallien P, Amarenco G, Benoit N et al (2014) Cranberry versus placebo in the prevention of urinary infections in multiple sclerosis: a\u00a0multicenter, randomized, placebo-controlled, double-blind trial. Mult Scler 20:1252\u20131259","journal-title":"Mult Scler"},{"key":"440_CR36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00345-013-1091-6","volume":"32","author":"B Kranjcec","year":"2014","unstructured":"Kranjcec B, Papes D, Altarac S (2014) D\u2011mannose powder for prophylaxis of recurrent urinary tract infections in women: a\u00a0randomized clinical trial. World J Urol 32:79\u201384","journal-title":"World J Urol"},{"key":"440_CR37","volume-title":"Guidelines on neuro-urology","author":"B Blok","year":"2015","unstructured":"Blok B, Pannek J, Castro Diaz D, European Association of Urology, - (2015) Guidelines on neuro-urology. \n                        https:\/\/uroweb.org\/wp-content\/uploads\/EAU-Guidelines-Neuro-Urology-2015-v2.pdf\n                        \n                    . Zugegriffen: 30.5.2016"},{"key":"440_CR38","first-page":"191","volume":"8","author":"JH Seth","year":"2014","unstructured":"Seth JH, Haslam C, Panicker JN (2014) Ensuring patient adherence to clean intermittent self-catheterization. Patient Prefer Adherence 8:191\u2013198","journal-title":"Patient Prefer Adherence"},{"key":"440_CR39","volume-title":"Management und Durchf\u00fchrung des Intermittierenden Katheterismus (IK) bei Neurogenen Blasenfunktionsst\u00f6rungen","author":"R B\u00f6thig","year":"2014","unstructured":"B\u00f6thig R, Geng V, Kurze I, DMGP (2014) Management und Durchf\u00fchrung des Intermittierenden Katheterismus (IK) bei Neurogenen Blasenfunktionsst\u00f6rungen. \n                        http:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/043-048l_S2k_Management_IK_Neurogene_Blasenfunktionsst\u00f6rungen_2016-10.pdf\n                        \n                    . Zugegriffen: 30.5.2016"},{"key":"440_CR40","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/1352458508098599","volume":"15","author":"L Vahter","year":"2009","unstructured":"Vahter L, Zopp I, Kreegipuu M et al (2009) Clean intermittent self-catheterization in persons with multiple sclerosis: the influence of cognitive dysfunction. Mult Scler 15:379\u2013384","journal-title":"Mult Scler"},{"key":"440_CR41","first-page":"63","volume":"5","author":"F Weckx","year":"2016","unstructured":"Weckx F, Tutolo M, De Ridder D et\u00a0al (2016) The role of botulinum toxin A in treating neurogenic bladder. Transl Androl Urol 5:63\u201371","journal-title":"Transl Androl Urol"},{"key":"440_CR42","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","volume":"60","author":"F Cruz","year":"2011","unstructured":"Cruz F, Herschorn S, Aliotta P et al (2011) Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a\u00a0randomised, double-blind, placebo-controlled trial. Eur Urol 60:742\u2013750","journal-title":"Eur Urol"},{"key":"440_CR43","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","volume":"187","author":"D Ginsberg","year":"2012","unstructured":"Ginsberg D, Gousse A, Keppenne V et\u00a0al (2012) Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J\u00a0Urol 187:2131\u20132139","journal-title":"J Urol"},{"key":"440_CR44","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eururo.2007.04.026","volume":"52","author":"B Schurch","year":"2007","unstructured":"Schurch B, Denys P, Kozma CM et\u00a0al (2007) Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol 52:850\u2013858","journal-title":"Eur Urol"},{"key":"440_CR45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2007.10.013","volume":"53","author":"G Karsenty","year":"2008","unstructured":"Karsenty G, Denys P, Amarenco G et\u00a0al (2008) Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity\/neurogenic overactive bladder: a\u00a0systematic literature review. Eur Urol 53:275\u2013287","journal-title":"Eur Urol"},{"key":"440_CR46","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2011.07.001","volume":"60","author":"A Mangera","year":"2011","unstructured":"Mangera A, Andersson KE, Apostolidis A et\u00a0al (2011) Contemporary management of lower urinary tract disease with botulinum toxin A: a\u00a0systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol 60:784\u2013795","journal-title":"Eur Urol"},{"key":"440_CR47","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1590\/S1677-55382011000500012","volume":"37","author":"S Deffontaines-Rufin","year":"2011","unstructured":"Deffontaines-Rufin S, Weil M, Verollet D et al (2011) Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients. Int Braz J Urol 37:642\u2013648","journal-title":"Int Braz J Urol"},{"key":"440_CR48","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0022-5347(01)62828-3","volume":"160","author":"G Buyse","year":"1998","unstructured":"Buyse G, Waldeck K, Verpoorten C et\u00a0al (1998) Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J\u00a0Urol 160:892\u2013896","journal-title":"J Urol"},{"key":"440_CR49","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.juro.2013.05.011","volume":"190","author":"P Krause","year":"2013","unstructured":"Krause P, Fuhr U, Schnitker J et\u00a0al (2013) Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study. J\u00a0Urol 190:1791\u20131797","journal-title":"J Urol"},{"key":"440_CR50","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/nau.22560","volume":"34","author":"M Humblet","year":"2015","unstructured":"Humblet M, Verpoorten C, Christiaens MH et al (2015) Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters. Neurourol Urodyn 34:336\u2013342","journal-title":"Neurourol Urodyn"},{"key":"440_CR51","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/1352458506075651","volume":"13","author":"M Seze de","year":"2007","unstructured":"de Seze M, Ruffion A, Denys P et\u00a0al (2007) The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 13:915\u2013928","journal-title":"Mult Scler"},{"key":"440_CR52","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/S0022-5347(05)67010-3","volume":"164","author":"EJ Chartier-Kastler","year":"2000","unstructured":"Chartier-Kastler EJ, Ruud Bosch JL, Perrigot M et al (2000) Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J\u00a0Urol 164:1476\u20131480","journal-title":"J Urol"},{"key":"440_CR53","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00192-009-1023-6","volume":"21","author":"SP Marinkovic","year":"2010","unstructured":"Marinkovic SP, Gillen LM (2010) Sacral neuromodulation for multiple sclerosis patients with urinary retention and clean intermittent catheterization. Int Urogynecol\u00a0J 21:223\u2013228","journal-title":"Int Urogynecol J"},{"key":"440_CR54","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00345-011-0669-0","volume":"30","author":"D Minardi","year":"2012","unstructured":"Minardi D, Muzzonigro G (2012) Sacral neuromodulation in patients with multiple sclerosis. World J Urol 30:123\u2013128","journal-title":"World J Urol"},{"key":"440_CR55","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00192-015-2771-0","volume":"27","author":"F Puccini","year":"2016","unstructured":"Puccini F, Bhide A, Elneil S et\u00a0al (2016) Sacral neuromodulation: an effective treatment for lower urinary tract symptoms in multiple sclerosis. Int Urogynecol\u00a0J 27:347\u2013354","journal-title":"Int Urogynecol J"},{"key":"440_CR56","first-page":"105","volume":"15","author":"DS Engeler","year":"2015","unstructured":"Engeler DS, Meyer D, Abt D et al (2015) Sacral neuromodulation for the treatment of neurogenic lower urinary tract dysfunction caused by multiple sclerosis: a\u00a0single-centre prospective series. BMC. Urology 15:105","journal-title":"Urology"},{"key":"440_CR57","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.urology.2011.06.015","volume":"78","author":"G Legrand","year":"2011","unstructured":"Legrand G, Roupret M, Comperat E et al (2011) Functional outcomes after management of end-stage neurological bladder dysfunction with ileal conduit in a\u00a0multiple sclerosis population: a\u00a0monocentric experience. Urology 78:937\u2013941","journal-title":"Urology"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-017-0440-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-017-0440-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-017-0440-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T07:29:36Z","timestamp":1518074976000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-017-0440-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,27]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["440"],"URL":"https:\/\/doi.org\/10.1007\/s00115-017-0440-x","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,27]]}}}